CD38JL Splice Variant Modulates Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective identification and characterization of novel genes involved in T cell activation, which are crucial for targeting autoimmune and inflammatory diseases, with CD38 being a multifunctional cell surface antigen but having unknown structural forms and functions.
Innovation Solution
The discovery and characterization of a novel CD38 splice variant, CD38JL, comprising an 81-amino acid polypeptide with ADP-ribosylcyclase activity, and its associated polynucleotides, which can be used as therapeutic agents or diagnostic tools for autoimmune and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to identify genes involved in T cell activation, then the identification process is limited, but novel gene discovery is insufficient
Solution Approach 1:
The patent applies segmentation by identifying and characterizing different splice variants (isoforms) of the CD38 gene, including the novel CD38JL variant. Each splice variant represents a segmented portion of the overall CD38 gene family, allowing systematic study of individual variants with distinct structures and functions. This approach enables comprehensive discovery of novel genes and variants involved in T cell activation while maintaining detailed structural and functional information for each segment.
2Reliability
If the complete CD38 gene structure is studied, then comprehensive functional information is obtained, but the complexity of analysis increases
Solution Approach 1:
The patent reduces analysis complexity by segmenting the CD38 gene into distinct splice variants, each with defined exon compositions. The novel CD38JL variant is characterized as comprising specific exons (exon 1, part of exon 2, exon 3, and alternative exon 4), creating a manageable segmented structure that maintains functional reliability while simplifying comparative analysis across variants.
Solution Approach 2:
The patent applies local quality by focusing characterization efforts on specific functional regions of each splice variant. The CD38JL variant is analyzed with attention to its unique exon 4 insertion and specific amino acid sequences, allowing detailed functional understanding of localized regions without requiring complete exhaustive analysis of entire gene structures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
CD38JL provides new compositions for treating and preventing inflammatory diseases like IBD, Psoriasis, and rheumatoid arthritis by modulating immune responses, and aids in diagnosis through specific polynucleotide detection and antibody production.
Implementation Method 1
CD38JL, which is a CD38 splice variant and comprises an 81 amino acid polypeptide... Amino Acid residues 1 through 57 of SEQ. ID. NO. 1 correspond to amino acid residues found in the CD38 sequence and with which ADP-ribosylcyclase activity is associated.
Data Source
AI summary
The invention provides for a substantially purified polypeptide referred to herein as CD38JL that is a CD38 splice variant comprised of the polypeptide of SEQ ID NO: 1 or a fragment thereof. The invention also provides methods for treating preventing and diagnosing disorders associated with expression of CD38JL.